Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ASND
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
seekingalpha.com
2 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Forecast
817%2026-Revenue
697%2026-EPS
-60037%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
230.00(15.23%)
Number of analyst
1
Last analyst upgrade/downgrade
Morgan Stanley
upgradePrevious: Equal-Weight
2025-05-05
Now: Overweight
RBC Capital
initialisePrevious: Not converted
2025-04-15
Now: Outperform
Cowen & Co.
upgradePrevious: Buy
2024-06-25
Now: Positive
Cowen & Co.
upgradePrevious: Not converted
2024-06-25
Now: Buy
Quote Panel
Key Metrics
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 Ć/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
NASDAQ
Unprofitable
Unprofitable
2.37Ā ( 1.20%)
Relative Strenght
78
Volume Buzz
-63%
Earning Acce
No
Dist 52w H.
4%Relative Strength
ASND
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-3.12
vsĀ -3.05
Q4.23
N/A
-1.66
vsĀ -3.78
Q1.24
N/A
-2.48
vsĀ -2.12
Q2.24
N/A
-2.05
vsĀ -2.35
Q3.24
N/A
-1.89
vsĀ -3.12
Q4.24
N/A
-0.68
vsĀ -1.66
Q1.25
N/A
-1.66
vsĀ -2.48
Q2.25
N/A
-0.93
vsĀ -2.05
Q3.25
N/A
-0.31
vsĀ -1.89
Q4.25
+110%
0.07
vsĀ -0.68
Sales Growth
YoY
Current
Estimates
Q3.23
+214%
48MĀ vsĀ 15.3M
Q4.23
+501%
137.7MĀ vsĀ 22.9M
Q1.24
+185%
95.9MĀ vsĀ 33.6M
Q2.24
-24%
36MĀ vsĀ 47.4M
Q3.24
+20%
57.8MĀ vsĀ 48M
Q4.24
+26%
173.9MĀ vsĀ 137.7M
Q1.25
+5%
101MĀ vsĀ 95.9M
Q2.25
+339%
158MĀ vsĀ 36M
Q3.25
+314%
239.2MĀ vsĀ 57.8M
Q4.25
+72%
298.5MĀ vsĀ 173.9M
Return on Equity
QoQ
Q1.23
-66%
-0.66
vsĀ -0.79
Q2.23
-187%
-1.87
vsĀ -0.66
Q3.23
+221%
2.21
vsĀ -1.87
Q4.23
+60%
0.6
vsĀ 2.21
Q1.24
+55%
0.55
vsĀ 0.6
Q2.24
+34%
0.34
vsĀ 0.55
Q3.24
+102%
1.02
vsĀ 0.34
Q4.24
+36%
0.36
vsĀ 1.02
Q1.25
+50%
0.5
vsĀ 0.36
Q2.25
NA
NA
vsĀ 0.5
Institutionnal Ownership
QoQ
Q1.23
179
179
vsĀ 204
-12%
Q2.23
175
175
vsĀ 179
-2%
Q3.23
174
174
vsĀ 175
-1%
Q4.23
202
202
vsĀ 174
16%
Q1.24
206
206
vsĀ 202
2%
Q2.24
215
215
vsĀ 206
4%
Q3.24
235
235
vsĀ 215
9%
Q4.24
224
224
vsĀ 235
-5%
Q1.25
255
255
vsĀ 224
14%
Q2.25
251
251
vsĀ 255
-2%